HAWPF Quote, Financials, Valuation and Earnings

CytoMed Therapeutics has a net margin of -- compared to Haw Par's net margin of --. Haw Par's return on equity of 6.62% beat CytoMed Therapeutics's return on equity of --.

Haw Par has a consensus price target of --, signalling downside risk potential of --. On the other hand CytoMed Therapeutics has an analysts' consensus of -- which suggests that it could grow by 78.77%. Given that CytoMed Therapeutics has higher upside potential than Haw Par, analysts believe CytoMed Therapeutics is more attractive than Haw Par.

Haw Par has a beta of 0.110, which suggesting that the stock is 88.956% less volatile than S&P 500. In comparison CytoMed Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Haw Par has a quarterly dividend of $0.15 per share corresponding to a yield of 3.6%. CytoMed Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haw Par pays 35.78% of its earnings as a dividend. CytoMed Therapeutics pays out -- of its earnings as a dividend. Haw Par's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haw Par quarterly revenues are --, which are smaller than CytoMed Therapeutics quarterly revenues of --. Haw Par's net income of -- is lower than CytoMed Therapeutics's net income of --. Notably, Haw Par's price-to-earnings ratio is 10.66x while CytoMed Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haw Par is 10.45x versus -- for CytoMed Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mobile-health Network Solutions has a net margin of -- compared to Haw Par's net margin of --. Haw Par's return on equity of 6.62% beat Mobile-health Network Solutions's return on equity of -1223.46%.

Haw Par has a consensus price target of --, signalling downside risk potential of --. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 2452.65%. Given that Mobile-health Network Solutions has higher upside potential than Haw Par, analysts believe Mobile-health Network Solutions is more attractive than Haw Par.

Haw Par has a beta of 0.110, which suggesting that the stock is 88.956% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Haw Par has a quarterly dividend of $0.15 per share corresponding to a yield of 3.6%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haw Par pays 35.78% of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend. Haw Par's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haw Par quarterly revenues are --, which are smaller than Mobile-health Network Solutions quarterly revenues of --. Haw Par's net income of -- is lower than Mobile-health Network Solutions's net income of --. Notably, Haw Par's price-to-earnings ratio is 10.66x while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haw Par is 10.45x versus 0.77x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Raffles Medical Group has a net margin of -- compared to Haw Par's net margin of --. Haw Par's return on equity of 6.62% beat Raffles Medical Group's return on equity of 5.89%.

Haw Par has a consensus price target of --, signalling downside risk potential of --. On the other hand Raffles Medical Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Haw Par has higher upside potential than Raffles Medical Group, analysts believe Haw Par is more attractive than Raffles Medical Group.

Haw Par has a beta of 0.110, which suggesting that the stock is 88.956% less volatile than S&P 500. In comparison Raffles Medical Group has a beta of 0.095, suggesting its less volatile than the S&P 500 by 90.471%.

Haw Par has a quarterly dividend of $0.15 per share corresponding to a yield of 3.6%. Raffles Medical Group offers a yield of 2.66% to investors and pays a quarterly dividend of $0.02 per share. Haw Par pays 35.78% of its earnings as a dividend. Raffles Medical Group pays out 78.41% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haw Par quarterly revenues are --, which are smaller than Raffles Medical Group quarterly revenues of --. Haw Par's net income of -- is lower than Raffles Medical Group's net income of --. Notably, Haw Par's price-to-earnings ratio is 10.66x while Raffles Medical Group's PE ratio is 27.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haw Par is 10.45x versus 2.41x for Raffles Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

WAVE Life Sciences has a net margin of -- compared to Haw Par's net margin of -167.19%. Haw Par's return on equity of 6.62% beat WAVE Life Sciences's return on equity of -437.99%.

Haw Par has a consensus price target of --, signalling downside risk potential of --. On the other hand WAVE Life Sciences has an analysts' consensus of $22.30 which suggests that it could grow by 65.43%. Given that WAVE Life Sciences has higher upside potential than Haw Par, analysts believe WAVE Life Sciences is more attractive than Haw Par.

Haw Par has a beta of 0.110, which suggesting that the stock is 88.956% less volatile than S&P 500. In comparison WAVE Life Sciences has a beta of -1.210, suggesting its less volatile than the S&P 500 by 220.988%.

Haw Par has a quarterly dividend of $0.15 per share corresponding to a yield of 3.6%. WAVE Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haw Par pays 35.78% of its earnings as a dividend. WAVE Life Sciences pays out -- of its earnings as a dividend. Haw Par's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haw Par quarterly revenues are --, which are smaller than WAVE Life Sciences quarterly revenues of -$7.7M. Haw Par's net income of -- is lower than WAVE Life Sciences's net income of -$61.8M. Notably, Haw Par's price-to-earnings ratio is 10.66x while WAVE Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haw Par is 10.45x versus 31.57x for WAVE Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.